High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention
- PMID: 20129566
- DOI: 10.1016/j.jcin.2009.10.024
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention
Abstract
Objectives: We tested the hypothesis that residual platelet reactivity after clopidogrel correlates with the extent and severity of coronary atherosclerosis in patients undergoing elective percutaneous coronary intervention (PCI).
Background: Platelets are actively involved in vascular atherosclerosis.
Methods: We prospectively enrolled 338 patients undergoing PCI for stable angina, loaded with 600-mg clopidogrel. Platelet reactivity was assessed 12 h later by measuring P2Y12 reactivity unit (PRU) with VerifyNow P2Y12 assay (Accumetrics, San Diego, California). High platelet reactivity (HPR) was defined as PRU value >or=240. Presence of multivessel disease (MVD) and total stent length (TSL) were used as surrogate markers of atherosclerosis severity and extension.
Results: Patients with MVD showed higher PRU compared with single-vessel disease (SVD) patients (222 +/- 85 vs. 191 +/- 73; p < 0.001). The PRU increased with the number of stenotic coronaries (1-vessel disease: 191 +/- 73; 2-vessel disease: 220 +/- 88; 3-vessel disease: 226 +/- 80; p = 0.002). The PRU was higher in the third TSL tertile compared with first tertile (217 +/- 83 vs. 191 +/- 73; p = 0.048). The HPR was most frequently observed among MVD patients (40.5% vs. 21.6% in patients with SVD, respectively; p < 0.001) and those in the third TSL tertile (35.8% vs. 22.2% first tertile; p = 0.028). Higher incidence of periprocedural myocardial infarction was observed in patients with HPR (41.2% vs. 26.7% in patients without HPR; p = 0.008) and in those in the third tertile TSL (37.7% vs. 23.1% first tertile; p = 0.020). By multivariate analysis, HPR was the only independent predictor of periprocedural myocardial infarction (p = 0.034).
Conclusions: Patients with more extensive coronary atherosclerosis have a higher rate of HPR, which might partly account for higher risk of periprocedural MI.
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.JACC Cardiovasc Interv. 2010 Mar;3(3):318-23. doi: 10.1016/j.jcin.2009.12.012. JACC Cardiovasc Interv. 2010. PMID: 20298992
-
A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.JACC Cardiovasc Interv. 2012 Mar;5(3):281-9. doi: 10.1016/j.jcin.2012.01.009. JACC Cardiovasc Interv. 2012. PMID: 22440493
-
Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.JACC Cardiovasc Interv. 2012 Mar;5(3):259-67. doi: 10.1016/j.jcin.2011.12.009. JACC Cardiovasc Interv. 2012. PMID: 22440490
-
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27. J Am Coll Cardiol. 2013. PMID: 24076493
-
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?Blood Coagul Fibrinolysis. 2016 Mar;27(2):117-20. doi: 10.1097/MBC.0000000000000406. Blood Coagul Fibrinolysis. 2016. PMID: 26340464 Review.
Cited by
-
Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.JAMA Cardiol. 2017 Dec 1;2(12):1380-1384. doi: 10.1001/jamacardio.2017.3868. JAMA Cardiol. 2017. PMID: 29071332 Free PMC article. Clinical Trial.
-
Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome.PLoS One. 2021 Feb 2;16(2):e0246166. doi: 10.1371/journal.pone.0246166. eCollection 2021. PLoS One. 2021. PMID: 33529262 Free PMC article.
-
Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis.J Thromb Thrombolysis. 2018 May;45(4):496-503. doi: 10.1007/s11239-018-1630-5. J Thromb Thrombolysis. 2018. PMID: 29450765
-
Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome.Chonnam Med J. 2017 May;53(2):147-152. doi: 10.4068/cmj.2017.53.2.147. Epub 2017 May 25. Chonnam Med J. 2017. PMID: 28584794 Free PMC article.
-
Clinical implications of platelet-vessel interaction.J Cardiovasc Transl Res. 2013 Jun;6(3):310-5. doi: 10.1007/s12265-012-9441-0. Epub 2012 Dec 28. J Cardiovasc Transl Res. 2013. PMID: 23271646 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous